Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors

British Journal of Pharmacology

Volumn 159, Issue 6, 2010, Pages 1326-1338

  Pires, I M ^a,b   Ward, T H ^a   Dive, C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Apoptosis; CHK2 inhibitor II; Colorectal cancer; Combination index; DBH; DNA cross links

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 2; CASPASE 3; CHECKPOINT KINASE 2; CHECKPOINT KINASE 2 INHIBITOR II; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOCHROME C; DEBROMOHYMENIALDISINE; OXALIPLATIN; PROTEIN BAX; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL STRAIN HCT116; COLORECTAL CANCER; CONTROLLED STUDY; DNA CROSS LINKING; DRUG POTENTIATION; ENZYME ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN STABILITY; UPREGULATION; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; COMET ASSAY; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; ORGANOPLATINUM COMPOUNDS; PROTEIN-SERINE-THREONINE KINASES; SMALL MOLECULE LIBRARIES; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; X-RAYS;

EID: 77949414415     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00607.x     Document Type: Article

References (49)

1. Ahn J, Urist M, Prives C (2003). Questioning the role of checkpoint kinase 2 in the p53 DNA damage response. J Biol Chem 278 (23): 20480-20489.
2. Almeida GM, Duarte TL, Steward WP, Jones GD (2006). Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay. DNA Repair (Amst) 5 (2): 219-225.
3. Antoni L, Sodha N, Collins I, Garrett MD (2007). CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nat Rev Cancer 7 (12): 925-936.
4. Arango D, Wilson AJ, Shi Q, Corner GA, Aranes MJ, Nicholas C et al. (2004). Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91 (11): 1931-1946.
5. Arienti KL, Brunmark A, Axe FU, McClure K, Lee A, Blevitt J et al. (2005). Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem 48 (6): 1873-1885.
6. Bartek J, Lukas J (2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3 (5): 421-429.
7. Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD et al. (2004). Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 10 (6): 2158-2167.
8. Bucher N, Britten CD (2008). G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 98 (3): 523-528.
9. Carrassa L, Broggini M, Erba E, Damia G (2004). Chk1 but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle 3 (9): 1177-1181.
10. Castedo M, Perfettini JL, Roumier T, Valent A, Raslova H, Yakushijin K et al. (2004). Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 23 (25): 4362-4370.
11. Chehab NH, Malikzay A, Appel M, Halazonetis TD (2000). Chk2/ hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 14 (3): 278-288.
12. Chipuk JE, Green DR (2006). Dissecting p53-dependent apoptosis. Cell Death Differ 13 (6): 994-1002.
13. Chou TC, Talalay P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
14. Cuadrado M, Martinez-Pastor B, Murga M, Toledo LI, Gutierrez-Martinez P, Lopez E et al. (2006). ATM regulates ATR chromatin loading in response to DNA double-strand breaks. J Exp Med 203 (2): 297-303.
15. Curman D, Cinel B, Williams DE, Rundle N, Block WD, Goodarzi AA et al. (2001). Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J Biol Chem 276 (21): 17914-17919.
16. Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel A et al. (2002). Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep 3 (3): 248-254.
17. Goldstein M, Roos W, Kaina B (2008). Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition.and Chk/p53 signaling. Toxicol Appl Pharmacol 229 (1): 20-32.
18. Hata T, Yamamoto H, Ngan CY, Koi M, Takagi A, Damdinsuren B et al. (2005). Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells. Mol Cancer Ther 4 (10): 1585-1594.
19. Heim M, Scharifi M, Zisowsky J, Jaehde U, Voliotis D, Seeber S et al. (2005). The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs 16 (2): 129-136.
20. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H et al. (2000). DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287 (5459): 1824-1827.
21. Jallepalli PV, Lengauer C, Vogelstein B, Bunz F (2003). The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J Biol Chem 278 (23): 20475-20479.
22. Kelland L (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7 (8): 573-584.
23. Lukas C, Falck J, Bartkova J, Bartek J, Lukas J (2003). Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat Cell Biol 5: 255-260.
24. Lukas J, Lukas C, Bartek J (2004). Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst) 3 (8-9): 997-1007.
25. Mathe G, Kidani Y, Segiguchi M, Eriguchi M, Fredj G, Peytavin G et al. (1989). Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 43 (4): 237-250.
26. Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J et al. (2001). Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 93 (8): 583-596.
27. Pabla N, Huang S, Mi QS, Daniel R, Dong Z (2008). ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatininduced apoptosis. J Biol Chem 283 (10): 6572-6583.
28. Pommier Y, Weinstein JN, Aladjem MI, Kohn KW (2006). Chk2 molecular interaction map and rationale for Chk2 inhibitors. Clin Cancer Res 12 (9): 2657-2661.
29. Rabik CA, Dolan ME (2007). Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33 (1): 9-23.
30. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E (2002). Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1 (3): 227-235.
31. Roos WP, Kaina B (2006). DNA damage-induced cell death by apoptosis. Trends Mol Med 12 (9): 440-450.
32. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P et al. (1990). Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82 (13): 1113-1118.
33. Saif MW, Kang SP, Chu E (2006). Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies. Oncology (Williston Park, N.Y.) 20 (14 Suppl. 10): 11-19.
34. Sambrook J, Russell DW (2001). Molecular Cloning - A Laboratory Manual, Vol. 1, 3rd edn. Cold Spring Harbor Laboratory Press: New York.
35. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S (2004). Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73: 39-85.
36. Scheeff ED, Briggs JM, Howell SB (1999). Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol 56 (3): 633-643.
37. Shieh SY, Taya Y, Prives C (1999). DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J 18 (7): 1815-1823.
38. Stevens C, Smith L, La Thangue NB (2003). Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 5 (5): 401-409.
39. Takemura H, Rao VA, Sordet O, Furuta T, Miao ZH, Meng L et al. (2006). Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks. J Biol Chem 281 (41): 30814-30823.
40. Troiani T, Lockerbie O, Morrow M, Ciardiello F, Eckhardt SG (2006). Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Mol Cancer Ther 5 (7): 1883-1894.
41. Ward TH, Danson S, McGown AT, Ranson M, Coe NA, Jayson GC et al. (2005). Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone. Clin Cancer Res 11 (7): 2695-2701.
42. Wen Q, Scorah J, Phear G, Rodgers G, Rodgers S, Meuth M (2008). A mutant allele of MRE11 found in mismatch repair-deficient tumor cells suppresses the cellular response to DNA replication fork stress in a dominant negative manner. Mol Biol Cell 19 (4): 1693-1705.
43. Wils J (2007). Adjuvant treatment of colon cancer: past, present and future. J Chemother 19 (2): 115-122.
44. Xu JM, Azzariti A, Colucci G, Paradiso A (2003). The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol 52 (6): 442-448.
45. Xu X, Tsvetkov LM, Stern DF (2002). Chk2 activation and phosphorylation-dependent oligomerization. Mol Cell Biol 22 (12): 4419-4432.
46. Yang S, Kuo C, Bisi JE, Kim MK (2002). PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol 4 (11): 865-870.
47. Zaugg K, Su YW, Reilly PT, Moolani Y, Cheung CC, Hakem R et al. (2007). Cross-talk between Chk1 and Chk2 in double-mutant thymocytes. Proc Natl Acad Sci USA 104 (10): 3805-3810.
48. Zhang J, Willers H, Feng Z, Ghosh JC, Kim S, Weaver DT et al. (2004). Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 24 (2): 708-718.
49. Zhivotovsky B, Orrenius S (2005). Caspase-2 function in response to DNA damage. Biochem Biophys Res Commun 331 (3): 859-867.